Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

ABSTRACT:

Introduction

In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised, monoclonal antibody that binds to and blocks interleukin-13 activity.

Methods

LUTE and VERSE were replicate, randomised, double-blind, placebo-controlled studies, evaluating multiple doses of lebrikizumab in patients with uncontrolled asthma despite the use of medium-to-high-dose inhaled corticosteroid and a second controller. Patients received lebrikizumab 37.5, 125, 250 mg or placebo subcutaneously every four weeks. The primary endpoint was the rate of asthma exacerbations during the placebo-controlled period. Analyses were performed on prespecified subgroups based on baseline ser

SUBMITTER: Hanania NA 

PROVIDER: S-EPMC4515999 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature